

## Researcher Spotlight

# AIMING TO PREVENT NOT JUST TREAT MPNS

## Dr. Angela Fleischman

In 2020, Cures Within Reach funded **Dr. Angela Fleischman** at the **University of California, Irvine** to support a Phase I/II trial testing an FDA-approved drug, N-Acetylcysteine, as a treatment for myeloproliferative neoplasm (MPNs), a group of blood cancers including polycythemia vera, essential thrombocythemia and myelofibrosis that cause blood clots and chronic inflammation.

She has received awards for her contributions to hematology and oncology, including the MPN Challenge Award, V Foundation Scholar Award, MPN Hero Award, and the 2021 Samuelli Scholar Award.

Dr. Fleischman's dedication to solving MPNs traces back to her days as a PhD student at Stanford University. She now leads an independent laboratory group dedicated to MPNs, driven by a vision where cancer is not just treated, but prevented altogether. Her overall goal: to identify what drives MPN disease initiation and to use this knowledge to develop therapies to treat or prevent this devastating disease. Dr. Fleischman hopes that someday "we will prevent, not treat, cancer."

### Profile



Dr. Angela Fleischman earned her medical degree and PhD from Stanford University and completed a fellowship at Oregon Health & Science University. She is an Associate Professor of Medicine in the Division of Hematology and Oncology at the University of California, Irvine with a commitment to MPNs.

### CWR Funding

This **Phase I/II clinical trial** is investigating N-acetylcysteine to reduce symptoms and blood clotting in MPN patients. Dr. Fleischman and this trial represent three of Cures Within Reach's communities:

- **Rare diseases**
- **Oncology**
- **Health Equity**